Antonio Martı́nez
YOU?
Author Swipe
View article: Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function
Clinical and Immunological Impact of JAK Inhibition in Concurrent Down Syndrome and STAT1 Gain of Function Open
Down syndrome (DS) and STAT1 gain-of-function (GOF) share clinical and molecular features, including persistent inflammation. We aimed to investigate whether the coexistence of DS and a STAT1 GOF mutation in a patient synergistically enhan…
View article: Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer Open
Young women with ER-positive, HER2-negative EBC have poorer outcomes. Ki67, in particular, is a poor prognostic marker in this group. Genomic profiling improves risk stratification and highlights unique tumor biology, supporting personaliz…
View article: A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias Open
Despite the remarkable clinical successes of chimeric antigen receptor (CAR) T-cell therapies in treating B-cell malignancies and multiple myeloma, similar outcomes have not been achieved in other indications. For patients with relapsed or…
View article: Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper
Indirect clinical validation for predictive biomarkers in oncology: International Quality Network for Pathology (IQN Path) Position Paper Open
View article: Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer Open
View article: <sup>18</sup> F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study
<sup>18</sup> F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study Open
18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.
View article: P1356: CD84-TARGETED CART-CELL THERAPY: A NOVEL STRATEGY FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES
P1356: CD84-TARGETED CART-CELL THERAPY: A NOVEL STRATEGY FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES Open
Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: Chimeric antigen receptor (CAR) T-cell therapies have achieved outstanding results in relapsed or refractory (R/R) B-cell malign…
View article: Margin control of lentigo maligna with <scp>SOX10</scp>‐frozen section immunostaining: A case series
Margin control of lentigo maligna with <span>SOX10</span>‐frozen section immunostaining: A case series Open
Mohs micrographic surgery is associated with an improved overall survival rate in patients with melanoma of the head and neck.1 However, visualizing melanocytes on frozen sections may be challenging. Although permanent section analyses are…
View article: P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation
P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation Open
p53 immunohistochemistry (IHC) has been proposed as a surrogate for TP53 mutations in penile squamous cell carcinomas (PSCC). We aimed to evaluate the performance of a pattern-based evaluation of p53 IHC in PSCC. Human papilloma virus (HPV…
View article: Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 64K
View article: Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
Purpose: Clinical responses to the immmunomodulatory drug lenalidomide have been observed in patients with relapsed/refractory mantle cell lymphoma (MCL), although its mechanism of action remains partially unknown. We investigated w…
View article: Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 78K
View article: Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Methods from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 78K
View article: Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Data from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
Purpose: Clinical responses to the immmunomodulatory drug lenalidomide have been observed in patients with relapsed/refractory mantle cell lymphoma (MCL), although its mechanism of action remains partially unknown. We investigated w…
View article: Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 3780K, (A) Accumulation of p27KIP1 and activated capase-3 in cytosol-enriched protein extracts from Rec-1 cells cultured for 72 h with 1 μmol/L lenalidomide and subjected to a Human apoptosis antibody array (R&D Systems).
View article: Data from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Data from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome Open
Purpose: Mutations in MYD88 are found in different lymphoproliferative disorders associated with particular biologic characteristics and clinical impact. The aim of this study was to analyze the incidence of MYD88 muta…
View article: Supplemental material from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Supplemental material from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome Open
1 - Serum and tumor cytokines according to MYD88 mutational status 2- Discrepancies in cell of origin distribution between gene expression and immunohistochemistry
View article: Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 1473K, Recounting of cells with nuclear positivity for cyclin D1 and p27KIP1 in (A) tumor specimen from two MCL patients presenting with a classical (Pt#1) or a blastoid (Pt#3)subtype and (B) in 6 MCL cell lines from either high…
View article: Data from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Data from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome Open
Purpose: Mutations in MYD88 are found in different lymphoproliferative disorders associated with particular biologic characteristics and clinical impact. The aim of this study was to analyze the incidence of MYD88 muta…
View article: Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 3 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 3780K, (A) Accumulation of p27KIP1 and activated capase-3 in cytosol-enriched protein extracts from Rec-1 cells cultured for 72 h with 1 μmol/L lenalidomide and subjected to a Human apoptosis antibody array (R&D Systems).
View article: Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure Legend from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 64K
View article: Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 6167K, (A) Flow cytometry analysis of cyclin D1 and p27KIP1 intracellular levels in a set of primary MCL samples (n=10, Table 1). In gray, isotypic control curves; in black, cyclin D1 and p27KIP1 curves. r indicates x-mean cycli…
View article: Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 2 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 6167K, (A) Flow cytometry analysis of cyclin D1 and p27KIP1 intracellular levels in a set of primary MCL samples (n=10, Table 1). In gray, isotypic control curves; in black, cyclin D1 and p27KIP1 curves. r indicates x-mean cycli…
View article: Supplemental material from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Supplemental material from <i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome Open
1 - Serum and tumor cytokines according to MYD88 mutational status 2- Discrepancies in cell of origin distribution between gene expression and immunohistochemistry
View article: Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes
Supplementary Figure 1 from Antitumoral Activity of Lenalidomide in <i>In Vitro</i> and <i>In Vivo</i> Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27<sup>KIP1</sup> Complexes Open
PDF file - 1473K, Recounting of cells with nuclear positivity for cyclin D1 and p27KIP1 in (A) tumor specimen from two MCL patients presenting with a classical (Pt#1) or a blastoid (Pt#3)subtype and (B) in 6 MCL cell lines from either high…
View article: <i>Ex vivo</i>confocal microscopy detects basic patterns of acute and chronic lesions using fresh kidney samples
<i>Ex vivo</i>confocal microscopy detects basic patterns of acute and chronic lesions using fresh kidney samples Open
Background Ex vivo confocal microscopy is a real-time technique that provides high-resolution images of fresh, non-fixed tissues, with an optical resolution comparable to conventional pathology. The objective of this study was to investiga…
View article: Access and quality of biomarker testing for precision oncology in Europe
Access and quality of biomarker testing for precision oncology in Europe Open
View article: Genetic and phenotypic characterisation of <scp>HIV</scp>‐associated aggressive B‐cell <scp>non‐Hodgkin</scp> lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Genetic and phenotypic characterisation of <span>HIV</span>‐associated aggressive B‐cell <span>non‐Hodgkin</span> lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications Open
The frequency of aggressive subtypes of B‐cell non‐Hodgkin lymphoma (B‐NHL), such as high‐grade B‐cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL‐DH/TH) or Burkitt‐like lymphoma (BL) with 11q aberration, is not well…
View article: Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer Open
View article: Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review
Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review Open
Penile squamous cell carcinoma (PSCC) is a rare but aggressive neoplasm with dual pathogenesis (human papillomavirus (HPV)-associated and HPV-independent). The development of targeted treatment is hindered by poor knowledge of the molecula…